All Stories

  1. Discovery of Bioactive Molecules via Miniaturized Parallel Modular Reactions and Rapid Screening (2016-2021 Update)
  2. SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions
  3. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019)
  4. Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors
  5. Recent applications of click chemistry in drug discovery
  6. Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d ]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors
  7. Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges
  8. Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014–2017)
  9. Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1
  10. Medicinal chemistry insights in the discovery of novel LSD1 inhibitors
  11. Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents
  12. Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors
  13. Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections
  14. Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations
  15. 8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential
  16. Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs
  17. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011 – 2014)
  18. “Old Dogs with New Tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets
  19. Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors
  20. “Old Friends in New Guise”: Exploiting Privileged Structures for Scaffold Re-Evolution/Refining
  21. Recent advances in the structure-based rational design of TNKSIs
  22. Heterocycle-thioacetic Acid Motif: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activities